Skin cancer screening and surveillance

British Journal of Dermatology

Volumn 146, Issue 5, 2002, Pages 745-754

  Osborne, J E ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; HIGH RISK POPULATION; HUMAN; MELANOMA; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK FACTOR; SKIN CANCER; SKIN PIGMENTATION; TRANSPLANTATION;

HUMANS; MASS SCREENING; MELANOMA; POPULATION SURVEILLANCE; SKIN NEOPLASMS;

EID: 0036103391     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04847.x     Document Type: Review

References (143)

1. Pevention and early detection strategies for melanoma and skin cancer
2. Screening for cutaneous melanoma by skin self-examination
3. Guidelines of care for nevi (nevocellular nevi and seborrheic keratoses)
4. Diagnosis and treatment of early melanoma
5. American College of preventive medicine policy statement: Screening of skin cancer
6. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high risk groups
7. Immediate effects of a public education campaign on prognostic features of melanoma
8. The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in Leicestershire
9. Audit of public education campaign to encourage earlier detection of malignant melanoma
10. The relation between mortality from malignant melanoma and early detection in the Cancer Research Campaign Mole Watcher Study
11. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi
12. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) naevi
13. Melanoma risk in individuals with clinically atypical nevi
14. Prevention and control of disease
15. Malignant melanoma in South Wales: Changing trends in presentation (1986-98)
16. Changing epidemiology of malignant melanoma in Queensland
17. Clinical accuracy of the diagnosis of cutaneous malignant melanoma
18. How well do physicians recognize melanoma and other problem lesions?
19. Referral pattern and accuracy of clinical diagnosis of cutaneous melanoma
20. Screening for melanoma and options for its evaluation
21. Screening for melanoma and other skin cancers
22. Basal cell carcinoma
23. Trends in non-melanocytic skin cancer treated in Australia: The second national survey
24. Skin cancer in a subtropical Australian population: Incidence and lack of association with occupation
25. Changing trends in nonmelanoma skin cancer in South Wales, 1988-98
26. The mysteries of geographic variability in nonmelanoma skin cancer incidence
27. How often does squamous cell carcinoma of skin metastasize?
28. Metastases from squamous cell carcinomas of the skin
29. Metastases in dermatological patients with squamous cell carcinoma
30. Malignant transformation of solar keratoses to squamous cell carcinoma
31. Sun education in Australia
32. Follow-up and evaluation of skin cancer screening in British Columbia
33. Complete follow-up and evaluation of a skin cancer screening in Connecticut
34. A two-year experience with a series of rural skin and oral cancer detection clinics
35. Volunteer melanoma screenings. Follow-up, compliance, and outcome
36. Audit of a melanoma screening day in the U.K.: Clinical results, patient satisfaction and perceived value
37. Melanoma/skin cancer screening in Michigan
38. Skin cancer detection clinics
39. Melanoma/skin cancer screening clinics: Experiences in the Netherlands
40. Lack of selective attendance of participants at skin cancer/melanoma screening clinics
41. Who comes to skin checks?
42. Skin cancer screening - A local experience
43. A campaign to fight malignant melanoma: A local experience in Berlin
44. Evaluation of melanoma/skin cancer screening in Massachusetts. Preliminary results
45. The use of targeted and non-targeted advertising to enrich skin cancer screening samples
46. Factors influencing participation among melanoma screening attenders
47. Who is being screened for melanoma/skin cancer? Characteristics of persons screened in Massachusetts
48. Motivating the public to take advantage of skin cancer screening
49. Importance of complete cutaneous examination for the detection of malignant melanoma
50. Total skin examination during screening for malignant melanoma does not increase the detection rate
51. Prevalence of early warning signs of melanoma among participants in the 1989 Rhode Island skin cancer screening
52. Skin cancer screening focusing on melanoma yields more selective attendance
53. Identifying people at high risk of cutaneous malignant melanoma: Results from a case control study in Western Australia
54. Benign melanocytic naevi as a risk factor for malignant melanoma
55. Number of melanocytic nevi as a major risk factor for malignant melanoma
56. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma
57. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: Multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society
58. The Danish case control study of cutaneous malignant melanoma. I. Importance of host factors
59. Self-reports of mole counts and cutaneous malignant melanoma in women: Methodological issues and risk of disease
60. Site-specific melanocytic naevus counts as predictors of whole body naevi
61. Malignant melanoma in England: Risks associated with naevi, freckles, social class, hair colour and sunburn
62. Common acquired naevi and the risk of malignant melanoma
63. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma
64. Self screening for risk of melanoma: Validity of self mole counting by patients in a single general practice
65. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study
66. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi
67. Risk gradient for malignant melanoma in individuals with dysplastic naevi
68. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma?
69. Teaching nonspecialist health care professionals how to identify the atypical mole syndrome phenotype: A multinational study
70. Risk factors for basal cell carcinoma in a Mediterranean population: Role of recreational sun exposure early in life
71. Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults
72. Value of follow-up after treatment of basal cell carcinoma
73. The risk of acquiring a new skin cancer in patients with previously diagnosed skin cancer. World Congress III on Cancers of the skin
74. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer
75. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma
76. Unresolved issues in the epidemiology of basal cell and squamous cell skin cancers
77. Truncal site detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma
78. Occurrence of other malignancies in 1973 patients with basal cell carcinoma
79. Risk for subsequent cancer after diagnosis of basal cell carcinoma
80. Basal cell carcinoma and risk of subsequent malignancies: A cancer registry-based study in southwest England
81. Basal cell carcinoma and actinic keratoses: Patients' perceptions of their disease and current treatments
82. Basal cell carcinoma
83. Cutaneous basal cell carcinomas: Distinct host factors are associated with the development of tumors on the trunk and on the head and neck
84. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma
85. Non-melanoma skin cancer and solar keratoses. II. Analytical results of the South Wales Skin Cancer Study
86. Epidemiology of actinic keratoses and squamous cell carcinoma
87. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: A case-control study
88. Prevalence of solar damage and actinic keratosis in a Merseyside population
89. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study
90. Is targeted early detection for melanoma feasible? Self assessments of risk and attitudes to screening
91. Feasibility of targeted early detection for melanoma: A population-based screening study
92. Who discovers melanoma? Patterns from a population-based survey
93. Incidence and reporting of cutaneous melanoma in Queensland
94. Investigating changes in awareness about cutaneous malignant melanoma in Britain using the Omnibus Survey
95. Malignant melanoma of the skin in upstate New York: Recent trends and characteristics
96. How much do the public know about moles, skin cancer and malignant melanoma? The results of a postal survey
97. Incidence of skin cancer in 5356 patients following organ transplantation
98. Post-transplant malignancy: The role of immunosuppression
99. Cutaneous malignant neoplasms in patients with renal transplants
100. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients
101. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients
102. Skin cancer in renal transplant recipients
103. Non-melanoma skin cancer in renal transplant recipients: The extent of the problem and a strategy for management
104. Cancer after kidney transplantation and immunosuppression
105. The risk of skin cancer in renal transplant recipients in Queensland, Australia
106. Skin cancer surveillance in renal transplant recipients: Questionnaire survey of current UK practice
107. One thousand renal transplants at Belfast City Hospital: Post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre
108. Cutaneous malignant melanoma. Publicity, screening clinics and survival - The Edinburgh experience 1982-90
109. Improving the early detection of malignant melanoma
110. A pigmented lesion clinic: Analysis of the first year's 1055 patients
111. Screening for melanoma by primary health care physicians: A cost-effectiveness analysis
112. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy
113. The sun and skin cancer. What you need to know about diagnosis and treatment
114. Evaluation of the American academy of dermatology's national skin cancer early detection and screening program
115. False negative clinical diagnosis of malignant melanoma
116. In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma
117. In vivo epiluminescence microscopy: Improvement of early diagnosis of melanoma
118. False-negative findings in skin cancer and melanoma screening
119. Aspects of screening for skin cancer
120. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy
121. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas
122. Presentation with multiple cutaneous basal cell carcinomas: Association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype
123. Glutathione S-transferase GSTP1 and cyclin D1 genotypes: Association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours
124. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation
125. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: A preliminary analysis
126. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma
127. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma
128. Cytochrome P450 CYP2D6 genotypes: Association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma
129. Association between functional polymorphism in EGF gene and malignant melanoma
130. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma
131. Fundamentals of skin cancer/melanoma screening campaigns
132. Skin cancer control in Australia: The balance between primary prevention and early detection